Stephen Tindal, director of science and technology at Catalent Pharma Solutions discusses what methods can be used to classify a drug’s solubility and bridge the divide between disciplines during development phases.
Bridging Divide
Commonly in the drug development process there is a disconnect between the chemical development of a molecule in the medicinal chemistry phase, and dosage form selection. This is more apparent in smaller research companies that focus on the earlier stages, where there may not be the resources to have extensive expertise across disciplines to guide development with a view to the longer term needs of the molecule.